118 related articles for article (PubMed ID: 12220726)
21. Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target.
Xiong X; Ke X; Wang L; Yao Z; Guo Y; Zhang X; Chen Y; Pang CP; Schally AV; Zhang H
Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6726-6732. PubMed ID: 32156725
[TBL] [Abstract][Full Text] [Related]
22. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
23. Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma.
Kiaris H; Schally AV; Varga JL; Groot K; Armatis P
Proc Natl Acad Sci U S A; 1999 Dec; 96(26):14894-8. PubMed ID: 10611309
[TBL] [Abstract][Full Text] [Related]
24. Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.
Ziegler CG; Brown JW; Schally AV; Erler A; Gebauer L; Treszl A; Young L; Fishman LM; Engel JB; Willenberg HS; Petersenn S; Eisenhofer G; Ehrhart-Bornstein M; Bornstein SR
Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15879-84. PubMed ID: 19717419
[TBL] [Abstract][Full Text] [Related]
25. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer.
Schally AV; Varga JL; Engel JB
Nat Clin Pract Endocrinol Metab; 2008 Jan; 4(1):33-43. PubMed ID: 18084344
[TBL] [Abstract][Full Text] [Related]
26. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma.
Irmer G; Bürger C; Müller R; Ortmann O; Peter U; Kakar SS; Neill JD; Schulz KD; Emons G
Cancer Res; 1995 Feb; 55(4):817-22. PubMed ID: 7850795
[TBL] [Abstract][Full Text] [Related]
27. Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors.
Jaeger LB; Banks WA; Varga JL; Schally AV
Proc Natl Acad Sci U S A; 2005 Aug; 102(35):12495-500. PubMed ID: 16118272
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
Engel JB; Keller G; Schally AV; Toller GL; Groot K; Havt A; Armatis P; Zarandi M; Varga JL; Halmos G
J Clin Endocrinol Metab; 2005 Jun; 90(6):3614-21. PubMed ID: 15784701
[TBL] [Abstract][Full Text] [Related]
30. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
[TBL] [Abstract][Full Text] [Related]
31. Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling.
Kanashiro CA; Schally AV; Zarandi M; Hammann BD; Varga JL
Int J Cancer; 2004 Nov; 112(4):570-6. PubMed ID: 15382037
[TBL] [Abstract][Full Text] [Related]
32. Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors.
Toller GL; Horvath JE; Schally AV; Halmos G; Varga JL; Groot K; Chism D; Zarandi M
Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15160-5. PubMed ID: 15469915
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES.1.
Roomi MW; Ivanov V; Kalinovsky T; Niedzwiecki A; Rath M
Oncol Rep; 2005 Feb; 13(2):253-7. PubMed ID: 15643507
[TBL] [Abstract][Full Text] [Related]
34. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
[TBL] [Abstract][Full Text] [Related]
35. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T
Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299
[TBL] [Abstract][Full Text] [Related]
36. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
37. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition.
Buchholz S; Seitz S; Schally AV; Engel JB; Rick FG; Szalontay L; Hohla F; Krishan A; Papadia A; Gaiser T; Brockhoff G; Ortmann O; Diedrich K; Köster F
Int J Oncol; 2009 Oct; 35(4):789-96. PubMed ID: 19724914
[TBL] [Abstract][Full Text] [Related]
38. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
Gründker C; Völker P; Schulz KD; Emons G
Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
[TBL] [Abstract][Full Text] [Related]
39. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon.
Hohla F; Moder A; Mayrhauser U; Hauser-Kronberger C; Schally AV; Varga JL; Zarandi M; Buchholz S; Huber R; Aigner E; Ritter M; Datz C
Int J Oncol; 2008 Jul; 33(1):137-43. PubMed ID: 18575759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
